-
公开(公告)号：US11813315B2
公开(公告)日：2023-11-14
申请号：US16276156
申请日：2019-02-14
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Sharon Cload , Linda Engle , Dasa Lipovsek , Malavi Madireddi , Ginger Chao Rakestraw , Joanna Swain , Wenjun Zhao , Hui Wei , Aaron P. Yamniuk , Vidhyashankar Ramamurthy , Alexander T. Kozhich , Martin J. Corbett , Stanley Richard Krystek, Jr.
IPC: A61K38/39 , C07K14/78 , C07K16/46 , A61K45/06 , G01N33/74 , A61K47/60 , C07K14/435 , C07K14/765 , C07K14/79 , C07K16/18 , A61K38/17 , A61K47/64 , A61K38/00
CPC classification number: A61K38/39 , A61K38/17 , A61K38/1709 , A61K45/06 , A61K47/60 , A61K47/642 , C07K14/435 , C07K14/765 , C07K14/78 , C07K14/79 , C07K16/18 , C07K16/46 , G01N33/74 , A61K38/00 , C07K2319/30 , C07K2319/31
Abstract: The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat muscular dystrophy, cachexia, sarcopenia, osteoarthritis, osteoporosis, diabetes, obesity, COPD, chronic kidney disease, heart failure, myocardial infarction, and fibrosis. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the proteins.
-
公开(公告)号：US20230051701A1
公开(公告)日：2023-02-16
申请号：US17737403
申请日：2022-05-05
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Nils Lonberg , Alan J. Korman , Bryan C. Barnhart , Aaron P. Yamniuk , Mohan Srinivasan , Karla A. Henning , Ming Lei , Emanuela Sega , Angela Goodenough , Maria N. Jure-Kunkel , Guodong Chen , John S. Sack , Richard Huang , Martin J. Corbett , Joseph E. Myers, JR. , Liang Schweizer , Sandra V. Hatcher , Haichun Huang , Pingping Zhang
IPC: C07K16/40 , C07K16/28 , C07K16/30 , A61K39/395 , G01N33/573 , A61K47/68 , A61K45/06 , G01N33/574
Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.
-
公开(公告)号：US20200071412A1
公开(公告)日：2020-03-05
申请号：US16687107
申请日：2019-11-18
Applicant: The Rockefeller University , BRISTOL-MYERS SQUIBB COMPANY
Inventor： Jeffrey V. Ravetch , Rony Dahan , Bryan C. Barnhart , Brigitte Devaux , Aaron P. Yamniuk , Shannon L. Okada , Brenda L. Stevens
IPC: C07K16/28
Abstract: Provided herein are agonistic antibodies, or antigen binding portions thereof, that bind to human CD40. Such antibodies optionally comprise Fc regions with enhanced specificity for FcγRIIb. The invention also provides methods of treatment of cancer or chronic infection by administering the antibodies of the invention to a subject in need thereof.
-
公开(公告)号：US20190300608A1
公开(公告)日：2019-10-03
申请号：US16371964
申请日：2019-04-01
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Achal Pashine , Michael L. Gosselin , Aaron P. Yamniuk , Derek A. Holmes , Guodong Chen , Priyanka Apurva Madia
Abstract: Provided herein are antibodies, or antigen-binding portions thereof, that specifically bind and inhibit TREM-1 signaling, wherein the antibodies do not bind to one or more FcγRs and do not induce the myeloid cells to produce inflammatory cytokines. Also provided are uses of such antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of autoimmune diseases.
-
公开(公告)号：US11952427B2
公开(公告)日：2024-04-09
申请号：US17694890
申请日：2022-03-15
Applicant: Bristol-Myers Squibb Company , CytomX Therapeutics, Inc.
Inventor： Bryan C. Barnhart , Brigitte Devaux , Aaron P. Yamniuk , Shannon L. Okada , Brenda L. Stevens , James William West
CPC classification number: C07K16/2878 , C12N15/63 , C07K2317/56
Abstract: Provided herein are agonistic antibodies, or antigen binding portions thereof, that bind to human CD40 and comprise improved heavy and light chain variable regions that impart improved yield and reduced aggregation. The invention also provides methods of treatment of cancer or chronic infection by administering the antibodies of the invention to a subject in need thereof.
-
Patent Agency Ranking
公开(公告)号：US11512124B2
公开(公告)日：2022-11-29
申请号：US16999291
申请日：2020-08-21
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Aaron P. Yamniuk , Stanley R. Krystek
Abstract: Provided herein are polypeptides comprising a modified fibronectin type III (Fn3) domain, wherein the amino acid corresponding to residue 58 of SEQ ID NO: 1 is mutated, and wherein the solubility is enhanced relative to the solubility of a Fn3 domain in which the amino acid corresponding to residue 58 of SEQ ID NO: 1 is not mutated. Also provided are libraries comprising a plurality of the polypeptides and a method for identifying a polypeptide that binds to a target.
-
公开(公告)号：US11352440B2
公开(公告)日：2022-06-07
申请号：US16117183
申请日：2018-08-30
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Nils Lonberg , Alan J. Korman , Bryan C. Barnhart , Aaron P. Yamniuk , Mohan Srinivasan , Karla A. Henning , Ming Lei , Emanuela Sega , Angela Goodenough , Maria N. Jure-Kunkel , Guodong Chen , John S. Sack , Richard Y. Huang , Martin J. Corbett , Joseph E. Myers, Jr. , Liang Schweizer , Sandra V. Hatcher , Haichun Huang , Pingping Zhang
IPC: A61K39/395 , C07K16/40 , C07K16/28 , C07K16/30 , G01N33/573 , A61K47/68 , A61K45/06 , G01N33/574 , A61K39/00
Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.
-
公开(公告)号：US11306149B2
公开(公告)日：2022-04-19
申请号：US16958563
申请日：2018-12-27
Applicant: Bristol-Myers Squibb Company , CytomX Therapeutics, Inc.
Inventor： Bryan C. Barnhart , Brigitte Devaux , Aaron P. Yamniuk , Shannon L. Okada , Brenda L. Stevens , James William West
Abstract: Provided herein are agonistic antibodies, or antigen binding portions thereof, that bind to human CD40 and comprise improved heavy and light chain variable regions that impart improved yield and reduced aggregation. The invention also provides methods of treatment of cancer or chronic infection by administering the antibodies of the invention to a subject in need thereof.
-
公开(公告)号：US11155618B2
公开(公告)日：2021-10-26
申请号：US16371964
申请日：2019-04-01
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Achal Pashine , Michael L. Gosselin , Aaron P. Yamniuk , Derek A. Holmes , Guodong Chen , Priyanka Apurva Madia , Richard Yu-Cheng Huang , Stephen Michael Carl
Abstract: Provided herein are antibodies, or antigen-binding portions thereof, that specifically bind and inhibit TREM-1 signaling, wherein the antibodies do not bind to one or more FcγRs and do not induce the myeloid cells to produce inflammatory cytokines. Also provided are uses of such antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of autoimmune diseases.
-
公开(公告)号：US10653791B2
公开(公告)日：2020-05-19
申请号：US15520954
申请日：2015-11-19
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Nils Lonberg , Alan J. Korman , Mark J. Selby , Bryan C. Barnhart , Aaron P. Yamniuk , Mohan Srinivasan , Karla A. Henning , Michelle Minhua Han , Ming Lei , Liang Schweizer , Sandra V. Hatcher , Arvind Rajpal
IPC: C07K16/00 , C07K16/28 , C07K16/30 , A61K47/68 , A61K39/395
Abstract: Provided herein are heavy chain constant regions (referred to as “modified heavy chain constant regions”), or functionally equivalent fragments thereof, that enhance biological properties of antibodies relative to the same antibodies in unmodified form. An exemplary modified heavy chain constant region includes an IgG2 hinge and three constant domains (i.e., CH1, CH2, and CH3 domains), wherein one or more of the constant region domains are of a non-IgG2 isotype (e.g., IgG1, IgG3 or IgG4). The heavy chain constant region may comprise wildtype human IgG domain sequences, or variants of these sequences. Also provided herein are methods for enhancing certain biological properties of antibodies that comprise a non-IgG2 hinge, such as internalization, agonism and antagonism, wherein the method comprises replacing the non-IgG2 hinge of the antibody with an IgG2 hinge.
-
-
-
-
-
-
-
-
-
Search Results
24
records
(took 0.022 seconds)
